A Phase 3, Prospective, Multicenter, Open-label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (ADYNOVATE) Administered for Prophylaxis and Treatment of Bleeding in Chinese Previously Treated Patients With Severe Hemophilia A (FVIII <1%)
Latest Information Update: 03 May 2025
At a glance
- Drugs Rurioctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Sponsors Takeda
Most Recent Events
- 20 Sep 2024 Status changed from active, no longer recruiting to completed.
- 08 Jul 2024 Planned End Date changed from 8 Oct 2025 to 9 Sep 2024.
- 08 Jul 2024 Planned primary completion date changed from 8 Oct 2025 to 9 Sep 2024.